SCHEMBL2336046

SCHEMBL2336046

COc1cccc2sc(SC)nc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
TDP1 Q9NUW8 3/20 0.61
CYP3A4 P08684 1/20 0.61
MAPT P10636 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
KDM4E B2RXH2 4/20 0.56
GAA P10253 2/20 0.56
F2RL3 Q96RI0 2/20 0.56
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
HPGD P15428 4/20 0.51
NPC1 O15118 3/20 0.51
TP53 P04637 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
DYRK1A Q13627 1/20 0.51
PPARG P37231 2/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693695 0.88 ALDH1A1 (0.63) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL6899691 0.88 ALDH1A1 (0.63) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL8635308 0.85 ALDH1A1 (0.59) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL31294145 0.81 ALDH1A1 (0.55) ALDH1A1TDP1CYP3A4MAPTMEN1
Hydrogen Sulfide SCHEMBL27509130 0.80 F2RL3 (0.40) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL6689383 0.79 ALDH1A1 (0.52) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL6691887 0.79 ALDH1A1 (0.52) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL3072555 0.77 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL3123406 0.77 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4MAPTMEN1
SCHEMBL5730270 0.77 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465882-B1 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-08-24 EP disclosed
US-7115640-B2 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. (US) 2006-10-03 US disclosed
EP-1465882-A4 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2005-04-06 EP disclosed
EP-1465882-A2 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP disclosed
US-20040180942-A1 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. 2004-09-16 US disclosed
US-6696473-B2 THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM X-CEPTOR THERAPEUTICS, INC. 2004-02-24 US disclosed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 WO disclosed
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 US disclosed
WO-2003060078-A2 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180942-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 ALDH1A1 2884/4885TDP1 4531/4885CYP3A4 245/4885
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 ALDH1A1 2884/4885TDP1 4531/4885CYP3A4 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.